Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Olopatadine hydrochlorideCat. No. 4241 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: (Z)-11-[3-(Dimethylamino)propylidene]-6,11-dihydro-dibenz[b,e]oxepin-2-acetic acid hydrochloride |
Biological Activity
Histamine H1 receptor antagonist (Ki = 31.6 nM). Inhibits the release of histamine, prostaglandin D2 and tryptase in a concentration-dependent manner. Mast cell stabilizer; inhibits mast cell mediator release. Also suppresses inflammation by inhibition of cytokine production.Certificate of Analysis / Safety Data Sheet
References
Sharif et al (1996) Characterization of the ocular antiallergic and antihistaminic effects of olopatidine (AL-4943A), a novel drug for treating ocular allergic diseases. J.Pharm.Exp.Ther. 278 1252.
Tamura et al (2007) Olopatidine ameliorates rat experimental cutaneous inflammation by improving skin barrier function. Pharmacology 81 118. PMID: 17962722.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Olopatadine hydrochloride, supplier, histamine, H1, antagonists, antihistamines, mast, cell, stabilizers, ocular, antiallergic
Quick Order
Find multiple products by catalog number
Histamine Review
Written by Iwan de Esch and Rob Leurs, leading experts. Request a copy or view PDF today.
7-TM Receptor Signaling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
New Therapies and Challenges in Asthma
Written by Peter J. Barnes
'New Therapies, Challenges, and Breakthroughs in Asthma' highlights key pathways and new therapies used to treat asthma, including those currently in clinical development.
New Products in this Area
Selective H4 agonist
Twitter Updates
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.